 Theres a question the CEO of Outlook Therapeutics Inc NASDAQ:OTLK likes to pose about why having US Food and Drug Administration FDA-approval will propel the companys upcoming treatment for retinal eye diseases to the top of the market. Say Im an eye care doctor. 